Crispr Therapeutics AG (CRSP) — Cash Flow-to-Debt Ratio
Crispr Therapeutics AG (CRSP) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-108.90 Million could theoretically repay 0% of its total liabilities ($911.26 Million) in one year. See CRSP free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crispr Therapeutics AG Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Crispr Therapeutics AG across 12 annual periods. For the full cash flow conversion analysis, see Crispr Therapeutics AG cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Crispr Therapeutics AG (2014–2025)
Year-by-year debt coverage analysis for Crispr Therapeutics AG. Check CRSP cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.00x | $-345.01 Million | $343.43 Million | ▼ -118.1% |
| 2024 | -0.46x | $-142.77 Million | $309.95 Million | ▲ +38.7% |
| 2023 | -0.75x | $-260.38 Million | $346.77 Million | ▲ +44.3% |
| 2022 | -1.35x | $-495.74 Million | $367.58 Million | ▼ -188.2% |
| 2021 | 1.53x | $538.97 Million | $352.42 Million | ▲ +205.1% |
| 2020 | -1.46x | $-238.37 Million | $163.73 Million | ▼ -427.1% |
| 2019 | 0.45x | $56.68 Million | $127.33 Million | ▲ +144.8% |
| 2018 | -0.99x | $-96.24 Million | $96.82 Million | ▼ -18.4% |
| 2017 | -0.84x | $-70.10 Million | $83.51 Million | ▼ -70.1% |
| 2016 | -0.49x | $-55.31 Million | $112.12 Million | ▼ -256.5% |
| 2015 | 0.32x | $59.43 Million | $188.55 Million | ▲ +155.9% |
| 2014 | -0.56x | $-4.79 Million | $8.50 Million | — |